A national patient registry for radiofrequency ablation (RFA) for Barrett's oesophagus

Conditions

Oesophageal Cancer/ Barrett's Oesophagus Cancer Malignant neoplasm of oesophagus

Magee CG, Graham D, Gordon C, Dunn J, Penman I, Willert R, Smart H, Ortiz-Fernandez-Sordo J, Ragunath K, Everson M, Alzoubaidi D, Banks M, Morris D, Sami S, Morris AJ, Bhandari P, Narayanasamy R, Di Pietro M, Lovat LB, Haidry R.

2021-02-053 citations

10.1007/s00464-021-08325-0

Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry

Rehan Haidry, M A Butt, Jason Dunn, Abhinav Gupta, Gideon Lipman et al. (23 authors)

Gut2014-12-2497 citations

10.1136/gutjnl-2014-308501

Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry.

Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, Green S, Miah H, Smart HL, Bhandari P, Smith LA, Willert R, Fullarton G, Morris J, Di Pietro M, Gordon C, Penman I, Barr H, Patel P, Boger P, Kapoor N, Mahon B, Hoare J, Narayanasamy R, O'Toole D, Cheong E, Direkze NC, Ang Y, Novelli M, Banks MR, Lovat LB.

2013-03-28156 citations

10.1053/j.gastro.2013.03.045

Interventions

HALO radiofrequency ablation (HALO RFA) The study collects the outcomes of patients undergoing the intervention which is RFA. The study collects not just demographic data on patients e

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients will be recruited from those referred for ablative management of Barrett's oesopahgus or squamous dysplasia with HALO RFA 2. Patients must have no contraindications to endoscopy 3. Males and non-pregnant females over the age of 21 years. Female patients who are pre-menopausal must practice a medically acceptable form of contraception. 4. Patients must sign an informed consent form

Exclusion criteria

Exclusion criteria: 1. Presence of invasive carcinoma of the oesophagus 2. Patients in whom endoscopy is contraindicated 3. Patients with oesophageal varices 4. Previous radiotherapy 5. Patients who have undergone Hellers myotomy 6. Pregnant females 7. People under the age of 21 years

Design outcomes

Primary

Measure	Time frame
1. Endoscopic clearance rate for Barrett's esophagus. Percentage of patients with no endoscopically visible Barrett's oesophagus at 1 year follow-up 2. Histological clearance rate for intestinal metaplasia. Percentage of patients with no histological evidence of intestinal metaplasia at 1 year follow-up 3. Histological clearance rate for columnar dysplasia. Percentage of patients with baseline dysplasia who have no histological evidence of dysplasia at 1 year follow-up 4. Sub-squamous intestinal metaplasia. Percentage of patients at 1 year follow-up with sub-squamous intestinal metaplasia, with or without dysplasia, that is covered completely by an intact layer of squamous epithelium with no communication with the surface	—

Measure

Time frame

1. Endoscopic clearance rate for Barrett's esophagus. Percentage of patients with no endoscopically visible Barrett's oesophagus at 1 year follow-up 2. Histological clearance rate for intestinal metaplasia. Percentage of patients with no histological evidence of intestinal metaplasia at 1 year follow-up 3. Histological clearance rate for columnar dysplasia. Percentage of patients with baseline dysplasia who have no histological evidence of dysplasia at 1 year follow-up 4. Sub-squamous intestinal metaplasia. Percentage of patients at 1 year follow-up with sub-squamous intestinal metaplasia, with or without dysplasia, that is covered completely by an intact layer of squamous epithelium with no communication with the surface

—

Secondary

Measure	Time frame
Ability of aneuploidy and other molecular changes to predict success or failure of this therapy.	—

Countries

United Kingdom

Outcome results

None listed